-
Notice of the General Department of the State Food and Drug Administration on Further Doing a Good Job in the Demonstration and Promotion of the Unique Identification of Medical Devices
The unique identification system for medical devices is an important measure to implement the "Regulations on the Supervision and Administration of Medical Devices", and effectively promote the reform of the State Council to control high-value medical consumables and the State Council to deepen the reform of the medical and health system. It is an important means to optimize management and promote the high-quality development of the industry. Since the implementation of the first batch of unique identifications for medical devices on January 1, 2021, the unique identifications have been successfully demonstrated and applied in the entire chain of medical device production, circulation and use, which has effectively promoted the entire process of medical devices from source production to clinical use. Chain linkage.
2022-01-29
-
State Food and Drug Administration deploys in-depth special rectification of drug safety
On January 24, the State Food and Drug Administration deployed in-depth special rectification actions for drug safety at the 2022 National Drug Supervision and Administration and Party Style and Clean Government Construction Work Conference. The meeting emphasized that it is necessary to conscientiously implement the spirit of General Secretary Xi Jinping's important instructions and the decision-making and deployment of the Party Central Committee, strengthen the "four consciousnesses", strengthen the "four self-confidences", and achieve "two maintenances", adhere to the people's health as the center, and conscientiously implement "Four strictest" requirements, strictly prevent and strictly control drug safety risks, and effectively ensure the safety and effectiveness of the people's medication, and take practical actions to welcome the victory of the Party's 20th National Congress.
2022-01-25
-
Announcement of the State Food and Drug Administration on Amending the Instructions for Clodronate Disodium Preparations (No. 135 of 2021)
According to the evaluation results of adverse drug reactions, in order to further ensure the safety of public medication, the State Drug Administration has decided to uniformly revise the contents of the instructions for clodronate disodium preparations.
2021-11-24
-
Five kinds of anti-tumor drugs on the market, including cisplatin injection, add information on medications for children
Recently, the State Food and Drug Administration issued an announcement that the corresponding specifications of the five anti-tumor drugs, cisplatin injection, ifosfamide for injection, azathioprine tablets, asparaginase for injection, and vindesine sulfate for injection, which have been marketed in China, are available. Refer to the announcement request to submit a supplementary application for amending the instructions to add information on children's medications. This is the second batch of announcements on the addition of children's drug information to the drug product inserts for marketed drugs since the State Food and Drug Administration launched the project to standardize children's drug use information in the drug product inserts already on the market.
2021-10-08
-
How did Guangdong quickly control the Lufeng epidemic?
What are the beneficial experiences in Guangdong's rapid and effective control of this epidemic? Duan Yufei, director of the Provincial Health Commission, stated that Guangdong’s work in dealing with this epidemic can be summarized as "six persistences" and emphasized two important points.
2021-07-14
-
Medical consumables supply catalog setting The "4+7" policy in the field of medical consumables has come
The National Health Commission issued the "Administrative Measures for Medical Consumables in Medical Institutions" (hereinafter referred to as the "Measures") on June 18, which not only strictly defines medical consumables, but also sets up a catalog of medical consumables for medical institutions...
2019-08-25
- Company Overview
- News
- Core Business
- Product Center
- Marketing Network
- Talents Wanted
- Contact Us
- Friendly Link： Guangzhou Zesheng Pharmaceutical Technology Co., Ltd
- Address：Address：35/F, Tower 3, Dongjun Plaza, No.836 Dongfeng East Road, Guangzhou
- Sales Department I：020-87620372
- Sales Department II：020-87675002
- Fax：020-87305940
Contact number for International business: Tel.: 020-37674724 Mobile: 15920406316 Email: iris@zeshengpharma.com
-
Applets
-
Pay attention to the public number